
Opinion|Videos|January 31, 2025
Patient Selection for Aflibercept 8 mg
Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Who is the ideal patient for aflibercept 8 mg?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
2
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
3
Q&A: Sharon Fekrat discusses retinal manifestations of antipsychotic medications
4
Navigating the Gray Zone in MacTel Type 2: When to Treat Early or Advanced Disease
5















































